Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Drug Profile

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Alternative Names: BMS-247616; S-1; Tegafur/gimeracil/oteracil; Teysuno; TS-1; TS-ONE

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Hepatocellular carcinoma; Uterine cancer
  • Phase II Oesophageal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 01 Mar 2018 Nordic Pharma completes phase III SALTO trial in Colorectal cancer (First-line therapy, Metastatic disease) in Netherlands (EudraCT2013-002147-28) (NCT01918852)
  • 25 Jan 2018 Taiho Pharmaceutical Company completes a phase II trial in Gastric cancer (In adults, In the elderly, First-line therapy, Monotherapy) in Japan (PO) (UMIN000021610)
  • 08 Sep 2017 Efficacy data from the phase III TRICOLORE trial in Colorectal cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top